BAAM
ARCT icon

Baker Avenue Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Baker Avenue Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,487
Closed -$161K – 255
2014
Q3 		$161K Sell
1,487
-684
-32% -$89.1K 0.02% 253
2014
Q2 		$263K Sell
2,171
-643
-23% -$77.6K 0.04% 240
2014
Q1 		$581K Buy
2,814
+1,100
+64% +$163K 0.09% 151
2013
Q4 		$216K Buy
+1,714
New +$215K 0.04% 225

Other funds holding ARCT

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Baker Avenue Asset Management's ARCT Position: Q4 2014 in Review

Baker Avenue Asset Management sold out of Arcturus Therapeutics (ARCT) in Q4 2014, closing a stake of 1,487 shares — an estimated $161K sold.

Baker Avenue Asset Management first reported a position in ARCT in Q4 2013 and held it in 4 quarters. The position peaked at $581K in Q1 2014. 28 funds tracked by Wall St. Rank hold ARCT as of Q4 2014.

  • Baker Avenue Asset Management reported no remaining Arcturus Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Baker Avenue Asset Management sold 1,487 Arcturus Therapeutics shares in Q4 2014, an estimated $161K.
  • Baker Avenue Asset Management first reported a position in Arcturus Therapeutics in Q4 2013 and held it in 4 quarters.
  • Baker Avenue Asset Management's Arcturus Therapeutics position peaked at $581K in Q1 2014.
  • 28 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2014.

Based on Baker Avenue Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.